Survivorship Programs for the Cancer Survivor: Next steps for the Modern Cancer Patient

Cancer remains a significant medical challenge for modern health care. Therapies have improved. Chemotherapy can now be applied and targeted to specific expression products and biomarkers. Radiation therapy is directed to specific targets with applied image guidance including less normal tissue in the treatment fields. Surgery has improved with robotics and improvements in rehabilitation and recovery. More patients are surviving their primary challenge from malignancy. As such, more patients now have the imprint of therapy upon their normal tissues. It is important for all practitioners, including primary care physicians and medical subspecialists, to participate in the aftercare of these patients with a comprehensive strategic manner to both prevent normal tissue injury and ameliorate injury if/when it occurs.

[1]  B. Jeremic,et al.  Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review , 2020, Radiation oncology.

[2]  N. Hanania,et al.  Radiation-Induced Lung Injury: Assessment and Management. , 2019, Chest.

[3]  J. Baima,et al.  Positioning of port films for radiation: variability is present , 2018, Medical Oncology.

[4]  Dinggang Shen,et al.  Radiation‐induced brain structural and functional abnormalities in presymptomatic phase and outcome prediction , 2018, Human brain mapping.

[5]  Sunil Krishnan,et al.  Radiation-Induced Cardiovascular Disease: A Clinical Perspective , 2017, Front. Cardiovasc. Med..

[6]  S. Huh,et al.  Insufficiency fracture after radiation therapy , 2014, Radiation oncology journal.

[7]  P. Hall,et al.  Risk of ischemic heart disease in women after radiotherapy for breast cancer. , 2013, The New England journal of medicine.

[8]  Joseph O Deasy,et al.  Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. , 2010, International journal of radiation oncology, biology, physics.

[9]  E. Yorke,et al.  Use of normal tissue complication probability models in the clinic. , 2010, International journal of radiation oncology, biology, physics.

[10]  R K Ten Haken,et al.  Partial irradiation of the liver. , 2001, Seminars in radiation oncology.

[11]  R. T. Ten Haken,et al.  Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[13]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[14]  M. Graham Predicting radiation response. , 1997, International journal of radiation oncology, biology, physics.

[15]  R. Jaszczak,et al.  Quantification of radiation-induced regional lung injury with perfusion imaging. , 1997, International journal of radiation oncology, biology, physics.

[16]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[17]  H. Withers,et al.  Treatment volume and tissue tolerance. , 1988, International journal of radiation oncology, biology, physics.